You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
This volume represents a compendium of scientific findings and approaches to the study of angiogenesis in cancer. The second edition of Antiangiogenic Agents in Cancer Therapy is intended to give a current perspective on the state-of-the-art of angiogenensis and therapy directed at this process. Antiangiogenesis is a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge.
Transforming Growth Factor-B in Cancer Therapy, Volume II: Cancer Treatment and Therapy The chapters in this volume confer an abundance of knowledge about the current state ofour understanding oftransforming growth factor-B (TGF-B) in cancer treatment and therapy. Unlike several more traditional positive polypeptide growth factors that stim ulate cellular proliferation, the prototypical TGF-B is now known to inhibit the growth of most normal cell types, including those of epithelial and mesenchymal origin. However, there are examplesofcell types that can be stimulated by TGF-B under certain conditions. TGF-B also induces the accumulation of matrix molecules by stimulating their synthesis as well as inhibiting their degradation. Moreover, TGF-B induces apoptosis of certain cell types, thereby restricting their proliferation. OveractivityofTGF-~ has been linked to several diseases. For instance, the effect ofTGF-~ on matrix accumulation contributes to fibrotic conditions, like glomerulonephritis, lung fibrosis and liver cirrhosis (1). TGF-~ has a very complicated role in cancer that is only beginning to be understood.
Transforming Growth Factor-jl in Cancer Therapy, Volume I: Basicand Clinical Biology The present volume brings together a wealth of information that is fundamental to understanding the roleofTGF-~ in the pathogenesis, prevention, and treatment of cancer. It is not even 25 years sinceTGF-~ was first isolated and characterized as a dimeric pep tide from both human and bovine sources (1-3), but the entire fieldofTGF-~ research has grown and expanded so that it is now a central theme in all of cell biology. There is almost no tissue or organ in the mammalian body in whichTGF-~ does not playa central role in embryonic differentiation or in adult function, and furthermore, malfunction of the normal physiologyofTGF-~can have disastrous consequences in almost all ofthese sites. Therefore, the present comprehensive review of so many aspects ofTGF-~ function is a most welcome attempt to bring together a huge body of experimental data that is of the utmost importance in the field of oncology.
Each issue is packed with extensive news about important cancer related science, policy, politics and people. Plus, there are editorials and reviews by experts in the field, book reviews, and commentary on timely topics.
This volume reviews advances in molecular biology and their applications to cancer prevention. The book presents papers important for both clinicians and researchers, written by experts in cancers of the colon, breast, skin, lung, bladder, and digestive tract.
Since Jan. 1901 the official proceedings and most of the papers of the American Association for the Advancement of Science have been included in Science.
None
The most recent advances in cancer prevention specifically in the areas of genetics, molecular biology, screening, and preventive trials are explored in depth by clinicians and researchers from around the world. The clinician will be able to apply this information to his or her practice, while the research scientist will gain insight into the clinical issues of prevention and early detection of cancer. Particular emphasis is placed on the prevention of breast, colon, and prostate cancer.